Increasing evidence supports the use of MRI fusion targeted biopsy (MRF-TB) to improve the detection of clinically significant prostate cancer (PCa) while limiting over-detection of indolent disease. We explored the relationship of serum PSA level and the relative outcomes of SB and MRF-TB.
1 August 2026 in Urologic Oncology: Seminars and Original Investigations